M42, a global health leader powered by technology, artificial intelligence, and genomics, and Arcera Life Sciences, a global life sciences company focused on advancing innovative and sustainable healthcare solutions, have signed a Memorandum of Understanding (MoU) to formalise a strategic, non-exclusive collaboration focused on advancing biopharma localisation, clinical development and next-generation healthcare innovation in Abu Dhabi.
Aligned with the Department of Health – Abu Dhabi’s (DoH) efforts to reinforce the Emirate’s position as a global hub for life sciences innovation, the collaboration will contribute to the development of an integrated life sciences ecosystem spanning clinical development and innovative therapeutics, addressing genetic and rare diseases with scalable treatments.
Under the collaboration, Arcera will work with M42 to leverage genomics data and query the genomics database to assess disease prevalence across specific genetic and rare diseases.
Combining genomics insights enabled by DoH, alongside M42’s advanced data platforms and healthcare delivery capabilities, with Arcera’s expertise in late-stage drug development, business development, and market access, the collaboration aims to accelerate the introduction of innovative therapies and improve patient access to advanced treatment solutions in the region.
The collaboration will deliver on four strategic pillars: Genomics-informed therapeutic development, Clinical development acceleration, Advanced biobanking, development of stem cell therapies and regenerative medicine, Digital and AI-enabled transformation.
Image caption- Dr Fahad Al Marzooqi, Chief Executive Officer, M42 Integrated Health Solutions (L); and Isabel Afonso, Chief Executive Officer, Arcera Life Sciences
